Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation' from buspar drug class Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 1:4 👁 View: 1.4M times ✓ Published: 12-Jun-2024
Description: Jim Cramer has expressed his confidence in Eli Lilly, LLY, citing the company’s diverse drug portfolio and the recent endorsement of its Alzheimer’s treatment by FDA advisors.